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The mechanisms of action of the potent antiarrhythmic
drug amiodarone are unknown. However, amiodarone
and its abundant metabolite, desethylamiodarone, bear
a striklng structural resemblance to thyroid hormones.
In addition, certain cardiac electrophysiologic effects of
amiodarone treatment are similar to those of hypothy-
roidism. These facts suggest that amiodarone or des-
ethylamiodarone could be acting, in part, by blocking
thyroid hormone action. Because thyroid hormones are
known to act through nuclear receptor protems, the
binding of amiodarone and desethylamiodarone was
measured to nuclear extracts derived from human lym-
phocytes, bovine atrium and ventricle and rat liver.
The capacity of increasing concentrations of amio-
darone and desethylamiodarone nuclear extracts to block
receptor binding of radiolabeled triiodothyronine (T3)
in a standard in vitro competition assay was tested. Nu-
clear extracts demonstrated only minimal binding to
Amiodarone is an important antiarrhythmic agent whose
mechanism of action is not yet fully understood. Current
information suggests that amiodarone may act through its
influence on nuclear receptors for thyroid hormone in target
tissues (I). Amiodarone and its abundant metabolite, des-
ethylamiodarone, are structurally similar to the physiolog-
ically active iodothyronines, thyroxine (Tot) and 3,5,3' -triiodo-
Lthyronine (T3 ) (Fig . I ). Furthermore, long-term amio-
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amiodarone. However, all receptor preparations had
substantial affinities (J(o) for the desethyl analog: lym-
phocyte, 8.6 ILM; atrium, 35.0 ILM; ventricle, 26.9 p.M
and liver, 8.6 p.M. Desethylamiodarone accumulates in
very large quantities in parenchymatous organs during
long-term amiodarone treatment. Taking its usual ther-
apeutic serum level (about 4 p.M or 2.7 p.g/ml) as an
estimate of intranuclear concentration, desethylamio-
darone would partially saturate nuclear thyroid hor-
mone receptors in several different tissues, including the
heart,
Thus, amiodarone treatment may exert some of its
electrophysiologic effects by metabolic conversion to
desethylamiodarone. This metabolite may then exclude
thyroid hormone froin nuclear receptor sites within the
myocardium.
(J Am Coli Cardiol 1987;9:872-6)
darone therapy is associated with prolongation in duration
of cardiac action potential and electrical refractoriness (2,3),
changes that may figure significantly in its antiarrhythmic
efficacy . These effects resemble electrophysiologic changes
occurring with hypothyroidism (4); they are prevented by
concomitant administration of thyroid hormone (2) .
These considerations have led to the concept that amio-
darone therap y may modulate the interaction of thyroid hor-
mone and its receptors in myocardium and other tissues.
However, no experimental data have been presented to eval-
uate a potential influence of amiodarone and its metabolites
on binding of thyroid hormone to tissue receptors . Such data
may be valuable in clarifying the mechanism behind the
metabolic alterations associated with long-term amiodarone
therap y. We therefore examined the capacity of amiodarone
and desethylamiodarone to compete for the binding of TJ
to specific nuclear thyroid hormone receptors in rat liver ,
bovine heart and human lymphocyte s. Rat liver was utilized
because nuclear thyroid hormone receptors from this tissue
have been the protot ype in numerous studies of the binding
properties of thyroid hormone analogs. Bovine heart pro-
vided an abundance of fresh tissue from each animal for
studies of myocardial nuclear thyroid hormone receptors .
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Figure l. Structural formulas for arniodarone , dcsethylamioda-
rone and thyroxine . Each molecule contains at least one diiodinated
aromatic ring and an ether linkage . Steric considerations suggest
that the optimal space-filling match occurs when the iodinated
aromati c ring of amiodarone or desethylamiodarone corre spond s
with the phenolic iod inated (rightward) ring of thyroxine .
Lymphocytes furnished the only readily accessible source
for nuclear thyroid hormone receptors in humans.
Methods
Reagents. High specifi c activity (' ~51 )3.5.3 ' -triiodo-L-
thyronine (' 25ITJ • 1.200 JLCi /JLg) was obtained from New
England Nuclear. Unlabeled triiodothyronine (T~) and thy-
roxine (T4) were purchased from Sigma Chemical Com-
pany. Chromatographically pure reverse 1'.1 was purchased
from Calbiochem-Behring . The unlabeled thyroid hormones
(T4. T3, reverse T3) were checked for purity by high per-
formance liquid chromatography as described previously
(5). T3 and reverse T1 contained less than 0 .5% contami-
nants (measured as optical density at wavelength 01'280 nrn)
and were used unpurified . Th yroxine intermittently con-
tained trace amounts of 3 ,5-T 2 and T3 and was purified when
necessary (6).
Pure powdered amiodarone and desethylamiodarone were
supplied by Sanofi Laboratories and were found to be ho-
mogeneous by high performance liquid chromatography (7).
Amiodarone and desethylamiodarone contained undetecta-
ble amounts of the opposite analog at detector sensitivities
that could identify 0.1 % contaminant. High performance
liqu id chromatography also confirined the solubility and
stability of amiodarone and desethylamiodarone in dilute
ethanol solutions. Stock solutions of amiodarone or des-
ethylamiodarone, 10 mM in pure ethanol, were diluted di-
rectly into assay buffer just before use. Assay preparations
containing various concentrations of either drug remained
clear and showed no evidence of precipitation during the
course of the experiments.
Receptor preparation. Solubilized nuclear thyroid hor-
mone receptors from rat liver . bovine atrium and bovine
.ventricle were prepared as described prev iously (6). Briefly ,
100 g of fresh tissue (rat liver, bovine ventricle or bovine
atrial appendage) was homogenized in 300 ml of warm
(37°C) 2.1 M sucrose solution containing 5.0 mM magne-
sium chloride and O. I mM phenylmethylsulfonylfluoride .
Nuclei were isolated from filtered homogenate by pelleting
through cold 2. 1 M sucrose (25, 000 x g for 2 h) . Nuclei
were washed in buffer (30 mMTri s, pH 7.6,2 mMcalcium
chloride , 1.1 mM magne sium chloride) containing 0.5%
Triton X- 100. then extracted in either 40 ml (liver) or 20
ml (atrium and ventricle) of buffer containing 0.2 M
(NH4hS04. The insoluble fraction was removed by cen-
trifugation (50,000 x g for 2 h) and the supernatant fraction,
containing thyroid hormone binding activity, was stored in
liquid nitrogen . Chromatin extracts were also prepared from
lymphocytes derived from euthyroid human donors as de-
scribed prev iously (8).
Hormone-binding studies. The relative receptor bind-
ing of each test compound was measured by binding site
competition between 125IT.\ and different concentrations of
each test compound: reverse T3 (30 nM to 10 p.M), amio-
darone and desethylamiodarone (0 .3 JLM to 0.1 rTIM) and
TJ and T4 (0 .1 nM to 30 nM). Hormone binding reactions
contained 0.1 nM mlT~ in a total reaction volume of 0 .5
ml. For saturation analy sis . bound hormone was separated
from free hormone on Sephadex G-25 columns (2 .0 ml bed
volume) as described previou sly (6) . Binding site compe-
tition between 1251T1 and nonradioactive TJ or T4 was not
influenc ed by the presen ce of maximal concentrations of the
solvent for amiodarone and desethylamiodarone (ethanol,
I% in assay buffer) .
Experimental conditions. The experiments reported
herein were conducted according to the principles set forth
in the' 'Guide for the Care and Use of Laboratory Animals,"
Institute of Laboratory Animal Resources , National Re-
search Council DHEW Pub . No. (NIH ) 74-23 .
Results
Binding to nuclear thyroid hormone receptors from
rat liver (Table 1, Fig. 2A). Liver nuclear extract bound
triiodothyronine (T3) best (equilibrium dissociation constant
KD = 0 .05 nM) with lower affinities for thyroxine (T4) (KI)
= 0.89 nM) and reverse T1(KD = 16.9 nM). These results
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are consistent with previous reports (6). Desethyl-
amiodarone demonstratedactive competition for T3binding
to the receptor but witha loweraffinity thanT3, T4 or reverse
T3 • Amiodarone did not show any competition in the con-
centration range tested. Thus, the desethylated analog of
amiodarone bound to the rat liver nuclear receptor (Kj, =
8.6 J-LM) whereas amiodarone did not bind.
Binding to human lymphocyte chromatin extracts
(Table I, Fig: 2B). Consistent with previous findings, we
observed abundant high affinity T3 (Ko = 1.2 oM) and T4
binding (Ko = 0.8 oM). Reverse T) had a higher affinity
in this mixed binding system than in rat liver (Kj,estimated:
0.9 oM). Desethylamiodarone again showed active binding
to this mixed receptor system (Ko = 8.6 J-LM. Amiodarone
also showed modest displacement of 125IT3, a result that
was not consistent with the findings in rat liver. However,
the apparent affinity of amiodarone for nuclear thyroid hor-
mone receptor was much less than that of desethylamio-
darone or any of the thyroid hormones. It is improbable that
this observed amiodarone binding was due to contamination
of the amiodarone with the desethylated analog because
nuclear thyroid hormone receptors derived from rat liver
did not show a similar amiodarone displacement and our
liquid chromatographic studies measuring the purity of the
crystalline compounds indicated no contamination of the
amiodarone with desethylamiodarone.
Figure 2. Percent binding of a radiolabeled 3,5 ,3 ' triiodo-L-thy-
ronine (125ITJ) to solubilized nuclear thyroid hormone receptors
plotted as a function of competitor concentration (hor izontal log-
arithmic axis). Nuclear thyroid hormone receptors were obtained
from rat liver (A), human lymphocytes (B), bovine atrium (C) and
bovine ventricle (D). Potency of inhibition of radioligand binding
indicates the relative affinity of each competitor for nuclear thyroid
hormone receptors, with greater potency indicated by a more left-
ward displacement of the competition curve . The relative analog
affinities were the same for receptors derived from liver, atrium
and ventricle: T3 > T4 > reverse T3 (RT3) > desethyl-
arniodarone (DA) > amiodarone (A). Human lymphocyte recep-
tors showed their characteristic higher affinity for T4 relative to
TJ • Amiodarone (open circles) showed only a minimal competition
for 125ITJ binding, indicating little or no affinity for nuclear thyroid
hormone receptors isolated from these tissues. The dashed line in
B shows a theoretical extrapolation of the reverse T3 results.
Binding to nuclear thyroid hormone receptors from
bovine atrium and ventricle (Table I, Fig. 2C and 2D).
Relative to the ventricle, atrium contained four to five times
as much T3 binding activity on a tissue wet-weight basis.
For atrium, the order and affi nitiesof hormone binding were
very similar to values obtained from rat liver (T3Ko = 0 .3
oM; T4 Ko = 1.7 oM; reverse TJ Ko = 39.8 oM). Des-
ethylamiodaroneagain showed full '25IT3displacement (Kj,
= 35.0 J-LM) with only slight 1251T3displacement by amio-
darone (estimated Ko = 220 J-LM ).
lA CC Vol. 9. No.4
April 1987:872-6
LATHAM ET AL.
AMIODARONE AND THYR OID HORMONE RECEPTORS
Table 1. Receptor Affinity for Tl, T4 , Reverse T, and Desethylamiodarone
Equilibrium Dissociation Constant (Kn)
Receptor Source T, (nM) T4I nM)* Reverse T, (nM)* DA ( p.M )*
Rat liver 0.05 0.89 16.9 8.6
Human lymphocyte 0.36 (l.O8 0.9 8.6
220t
Bovine atrium 0.30 1.7 39.8 35.0
Bovine ventricle 10.1 79 3.300 26.9
*Kn = [(Csn) (KDTJ» )/[(KDT1 + 1251Tdl. where C", = molar concentration of competitor at 50% inhibition
of T3 binding KilTJ is the Kn of T, binding; 12SIT, = the molar concentration of the radiolabeled T, (0.1 nM
in thesestudies). t Kn for amiodarone binding to receptors from human lymphocytes. DA = desethylarniodarone.
X75
Although material obtained from the ventricle showed
less T, binding activity and lower affinity binding (T, KIJ
= 10.1 nM; T4 KD = 79 nM; reverse T, Kn = 3.3 J.LM )
than the atrium, the order of hormone preference was the
same in ventricle, atrium and rat liver. As in the atrium.
desethylamiodarone showed active receptor binding (KD =
26.9 J.LM) ; amiodarone exhibited a small amount of dis-
placement.
Discussion
Desethylamiodarone competition for thyroid hor-
mone receptors. Our results demonstrate that desethyla-
miodarone has a substantial capacity to compete for thyroid
hormone binding to nuclear thyroid hormone receptors de-
rived from three different tissues in three different species.
including humans. In general. this capability is not shared
by the parent compound, amiodarone, although some weak
competitive binding is noted in human lymphocytes (Fig.
2B). This capacity suggests that desethylamiodarone may
be able to influencemetabolic processes governed by thyroid
hormone in a variety of tissues. Desethylamiodarone has a
much lower affinity for nuclear thyroid hormone receptors
than triiodothyronine (T,) or thyroxine (T4 ) (Table J). How-
ever, very large amounts of desethylamiodarone accumulate
in parenchymatous organs of treated subjects (up to 6.500
rng/kg in human liver) (9). Steady state blood concentra-
tions of desethylamiodarone in patients on long-term amio-
darone therapy approximate 4 J.LM (2.7 J.Lg/ml) (10). If sim-
ilar concentrations appear in cell nuclei, our data suggest
that partial saturation of nuclear thyroid hormone receptors
by desethylamiodarone is a distinct possibility. Thus. des-
ethylamiodarone competition for thyroid hormone receptors
may be signifi cant in the clinical use of this drug. both as
a potential source of beneficial antiarrhythmic action, and
as a factor in genesis of side effects in the many organ
systems infl uenced by amiodarone treatment.
In addition to the binding properties of desethylamio-
darone, our findings also demonstrate an even higher affinity
of nuclear thyroid hormone receptors for reverse T,. Be-
cause long-term amiodarone treatment results in a two- to
fourfold rise in serum reverse T, levels (I), greater reverse
T, occupancy of nuclear thyroid hormone receptor sites is
a possible outcome of this therapy. The metabolic conse-
quences of such a change are, at present. unknown. How-
ever. higher reverse TJ levels could also act, possibly in
concert with desethylamiodaronc, to displace thyroid hor-
mone from its nuclear receptor and thereby contribute to a
hypothyroid state within the heart or other tissues.
Role of blockade of thyroid hormone receptors in anti-
arrhythmic effects of amiodarone. Thyroid hormone lev-
els clearly modulate myocardial repolarization. Isolated
myocardium from thyroidectomized rabbits exhibits pro-
longation in the plateau phase of the action potential (4).
Singh and Vaughan Williams (2) demonstrated that long-
term amiodarone therapy produces repolarization delay sim-
ilar to that caused by thyroidectomy. The repolarization
changes induced by amiodarone can be prevented by con-
comitant thyroid hormone treatment (2). More recently, Singh
and Nademanee ( I) suggested that amiodarone therapy may
influence cardiac muscle. in part. by blocking the actions
of T, on nuclear thyroid hormone receptors. Our findings
provide explicit experimental support for this concept by
demonstrating a potential for blockade of nuclear thyroid
hormone receptors in heart and other tissues during amio-
darone therapy and by identifying a specific molecular spe-
cies most likely responsible for this blockade. Transfor-
mation of amiodarone to desethylamiodarone and subsequent
blockade induced by this metabolite may explain the early
electrophysiologic results.
This postulated action of desethylamiodarone is conso-
nant with present knowledge of the pharmacokinetic and
pharmacodynamic aspects of amiodarone therapy in man.
Thus, the long delay in onset of maximal antiarrhythmic
efficacy of oral therapy and the relatively modest effects on
repolarization with intravenous dosing despite equivalent
blood and tissue levels of amiodarone may be explained by
a requirement to convert amiodarone to desethylamioda-
rone, accumulate large intracellular stores of desethylamio-
darone and await the relatively slow changes that would be
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expected with blockade of nuclear thyroid hormone recep-
tors.
If desethylamiodarone competition for T, and T4 binding
to nuclear thyroid hormone receptors is responsible, in part,
for certain cardiac effects of amiodarone therapy, then de-
sethylamiodarone must occupy the receptor site without ac-
tivation. Such a blocking effect would be unique among
various substances known to interact with nuclear thyroid
receptors. In the past, an extensive survey of thyroid hor-
mone analogs failed to identify any compound with receptor
antagonist properties (10).
If blockade of nuclear thyroid receptors is an important
mediator of the cardiac actions of amiodarone therapy, this
leaves unexplained the fact that effective amiodarone ther-
apy is not uniformly accompanied by clinically overt gen-
eralized hypothyroidism. Although hypothyroidism devel-
ops in an appreciable number of patients receiving amiodarone,
such patients generally have reduced levels of plasma T,
and T4 , an effect usually ascribed to an unusual metabolic
response to the abnormal iodide load released with metabolic
breakdown of amiodarone and desethylamiodarone (I, II).
Current results offer no suggestion of myocardial selectivity
for desethylarniodarone, because this substance appears able
to bind nuclear thyroid hormone receptor sites with a similar
affinity in all tissues studied (Table I). These results do
suggest that receptor affinity for T, is distinctly lower in the
ventricles. This could permit desethylamiodarone to com-
pete with T, more effectively in the ventricles than in other
tissues. Such an explanation would not apply to the atria,
which exhibit a clinical sensitivity to antiarrhythmic actions
of amiodarone therapy exceeding that of the ventricles.
Therapeutic implications of the study. Caution must
be used in interpreting our results. Relative concentrations
of desethylamiodarone, arniodarone, reverse T" T, and T4
in the vicinity of nuclear thyroid hormone receptors during
long-term amiodarone therapy is unknown. In addition, the
relation between nuclear thyroid hormone receptors and
electrical functioning of the myocardium is uncertain. Other
thyroid hormone receptors (for example, those on plasma
membrane) may also be important in mediating thyroid hor-
mone action on electrical activity. Ultimate determination
of the capacity of amiodarone and desethylamiodarone to
influence thyroid hormone action in the heart and other
tissues must rely on measurement of metabolic indexes.
Certain cardiac electrophysiologic effects of amiodarone
therapy have no apparent connection with blockade of nu-
clear thyroid hormone receptors, for example, blockade of
inactivated sodium channels (12,13). Moreover, the relation
of potential thyroid-mediated changes (delayed repolariza-
tion and prolonged refractoriness) and antiarrhythmic effi-
cacy has not been fully delineated.
The electrophysiologic and clinical effects of long-term
treatment with independently administered desethylamio-
darone are unknown. Electrophysiologic studies to date have
focused on results of short-term administration of desethyl-
amiodarone (14), at time points before any likely influence
resulting from inhibition of nuclear thyroid hormone recep-
tors. Despite this multitude of uncertainties, our results sug-
gest that further exploration of nuclear thyroid hormone
receptor blockade may elucidate important aspects of anti-
arrhythmic efficacy and other consequences of amiodarone
therapy.
We thank Sanofi Laboratories, Inc. for providing research samples of
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thank Angela James for expert editorial assistance.
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